Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study
An erratum to this article was published (Ann Rheum Dis, Nov 2026 ↗)
Authors' conclusion
Romosozumab was associated with a lower risk of osteoarthritis than teriparatide among individuals with osteoporosis, particularly for knee osteoarthritis. Similar trends were observed for hip and hand osteoarthritis; however, the differences were not significant.
Study context
- Population
- Individuals aged ≥50 years with osteoporosis in an administrative claims database, 2019–2022 (87% female; mean age 80 years)
- Participants
- 22,145 individuals
- Comparison
- Romosozumab vs teriparatide
- Outcome
- Incidence of osteoarthritis
- Follow-up
- 1 year
Methodological detailsnew user comparative effectiveness study, active comparator, inverse probability of treatment weighting (IPTW), inverse probability of censoring weighting (IPCW), weighted Kaplan-Meier estimator
- New user comparative effectiveness study
- Active comparator
- IPTW
- IPCW
- Weighted Kaplan-Meier estimator
Main finding
As reported in the abstract
Incident osteoarthritis
Each group vs teriparatideRelative risk (95% CI)
Romosozumab
0.79(0.66–0.89)
- Romosozumab
- Absolute risk reduction (ARR) 1.1% (95% CI 0.5%–1.8%)
Parts of this Brief are withheld: the automatic checks could not confirm them against the abstract.
Original publication
Osteoarthritis risk associated with romosozumab compared with teriparatide in individuals with osteoporosis: a target trial emulation study. Ann Rheum Dis. Published 11 July 2025. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →